A comprehensive view of U.S. Food and Drug Administration (FDA). This page highlights a small sample of our full coverage.
For real-time access, please log in to your Bioeconomy Market Intelligence Service.
Roche receives FDA approval for the first molecular test to screen for malaria in blood donors
Published:
March 26, 2024
by F. Hoffmann-La Roche Ltd. (Roche)
|
FDA approves Roche's cobas Malaria test for use on the cobas 6800/8800 Systems, making it the first molecular test for malaria screening in US; malaria affected about 292 million people in 2022, with Africa accounting for 94% of cases
Published:
March 26, 2024
by GlobeNewswire Europe
|
FDA grants Fast Track designation to J&J's nipocalimab injectable for FNAIT treatment, a potentially life-threatening condition affecting pregnant women's immune response to fetal platelets; it is the only therapy in clinical development for the disorder
Published:
March 26, 2024
by Janssen Pharmaceutical Companies
|
American Heart Association applauds federal appeals court decision upholding FDA’s graphic cigarette warnings on cigarette packs and advertisements; court calls the warnings 'factual and uncontroversial', says they do not violate first amendment
Published:
March 25, 2024
by Contify Life Science News
|
FDA approves Ultomiris from Alexion, AstraZeneca Rare Disease; the drug is used to treat adult patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder, a rare neurological disease
Published:
March 25, 2024
by AstraZeneca AB
|
Ask us about our Bioeconomy market view